Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TAAR1 | Q96RJ0 | 5/20 | 0.53 |
| ▸ | LTC4S | Q16873 | 6/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.36 |
| ▸ | SLC16A3 | O15427 | 1/20 | 0.36 |
| ▸ | SLC16A1 | P53985 | 1/20 | 0.36 |
| ▸ | KDM4C | Q9H3R0 | 1/20 | 0.36 |
| ▸ | MTNR1A | P48039 | 1/20 | 0.34 |
| ▸ | MTNR1B | P49286 | 1/20 | 0.34 |
| ▸ | REN | P00797 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2082341 | 0.88 | TAAR1 (0.53) | TAAR1 | |
| SCHEMBL29920949 | 0.88 | TAAR1 (0.53) | TAAR1 | |
| SCHEMBL2082338 | 0.88 | TAAR1 (0.53) | TAAR1 | |
| SCHEMBL20972890 | 0.80 | SLC16A3 (0.37) | LTC4SSMN1; SMN2SLC16A3SLC16A1KDM4C | |
| SCHEMBL2079030 | 0.79 | TAAR1 (0.52) | TAAR1LTC4S | |
| SCHEMBL2079027 | 0.79 | TAAR1 (0.52) | TAAR1LTC4S | |
| SCHEMBL2081964 | 0.77 | TAAR1 (0.52) | TAAR1 | |
| SCHEMBL2081963 | 0.77 | TAAR1 (0.52) | TAAR1 | |
| SCHEMBL2081176 | 0.73 | TAAR1 (0.64) | TAAR1 | |
| SCHEMBL2080124 | 0.73 | TAAR1 (0.64) | TAAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10858326-B2 | Oxazoline pseudodimers, pharmaceutical compositions and the use thereof | PURDUE PHARMA L.P. (US) | 2020-12-08 | — | — | US | disclosed |
| US-20190144400-A1 | OXAZOLINE PSEUDODIMERS, PHARMACEUTICAL COMPOSITIONS AND THE USE THEREOF | PURDUE PHARMA L.P. (US) | 2019-05-16 | — | — | US | disclosed |
| WO-2017192858-A1 | OXAZOLINE PSEUDODIMERS, PHARMACEUTICAL COMPOSITIONS AND THE USE THEREOF | PURDUE PHARMA L.P. (US) | 2017-11-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10858326-B2 | Oxazoline pseudodimers, pharmaceutical compositions and the use thereof | OPRM1, OPRD1, CYP3A7 | TAAR1 2075/4885LTC4S 2541/4885SMN1; SMN2 627/4885 |
| US-20190144400-A1 | OXAZOLINE PSEUDODIMERS, PHARMACEUTICAL COMPOSITIONS AND THE USE THEREOF | OPRM1, OPRD1, CYP3A7 | TAAR1 2075/4885LTC4S 2541/4885SMN1; SMN2 627/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.